Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Logothetis

Showing results (31-40 of 86) with videos related to

Pageof 9
Sort By:
The Journal of Urology|July 29, 2020
The Association of Periprostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active SurveillanceJustin R Gregg, Devaki Shilpa Surasi, Alexandria Childs, et al.
Cancer|October 10, 2006
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinomaNizar M Tannir, Lorenzo Cohen, Xuemei Wang, et al.
Current Medical Research and Opinion|July 27, 2007
The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groupsJanet van Adelsberg, Peter Gann, Amy T Ko, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 10, 2009
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissuesHong Chen, Chrysoula I Liakou, Ashish Kamat, et al.
Molecular & Cellular Proteomics : MCP|December 21, 2014
Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironmentYu-Chen Lee, Martina Srajer Gajdosik, Djuro Josic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2014
Aggressive variants of castration-resistant prostate cancerHimisha Beltran, Scott Tomlins, Ana Aparicio, et al.
Oncogene|March 13, 2019
Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancerKrishna M Sinha, Rozita Bagheri-Yarmand, Sharmistha Lahiri, et al.
Journal of the National Cancer Institute|June 8, 2006
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancerSun-Jin Kim, Hisanori Uehara, Sertac Yazici, et al.
BMC Medical Genomics|February 2, 2008
Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancerTimothy J McDonnell, Nikhil S Chari, Jeong Hee Cho-Vega, et al.
Oncogene|June 15, 2021
Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in boneTianhong Pan, Song-Chang Lin, Yu-Chen Lee, et al.
Pageof 9

Showing results (31-40 of 86) with videos related to

Sort By:
Pageof 9
The Journal of Urology|July 29, 2020
The Association of Periprostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active SurveillanceJustin R Gregg, Devaki Shilpa Surasi, Alexandria Childs, et al.
Cancer|October 10, 2006
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinomaNizar M Tannir, Lorenzo Cohen, Xuemei Wang, et al.
Current Medical Research and Opinion|July 27, 2007
The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groupsJanet van Adelsberg, Peter Gann, Amy T Ko, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 10, 2009
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissuesHong Chen, Chrysoula I Liakou, Ashish Kamat, et al.
Molecular & Cellular Proteomics : MCP|December 21, 2014
Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironmentYu-Chen Lee, Martina Srajer Gajdosik, Djuro Josic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2014
Aggressive variants of castration-resistant prostate cancerHimisha Beltran, Scott Tomlins, Ana Aparicio, et al.
Oncogene|March 13, 2019
Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancerKrishna M Sinha, Rozita Bagheri-Yarmand, Sharmistha Lahiri, et al.
Journal of the National Cancer Institute|June 8, 2006
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancerSun-Jin Kim, Hisanori Uehara, Sertac Yazici, et al.
BMC Medical Genomics|February 2, 2008
Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancerTimothy J McDonnell, Nikhil S Chari, Jeong Hee Cho-Vega, et al.
Oncogene|June 15, 2021
Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in boneTianhong Pan, Song-Chang Lin, Yu-Chen Lee, et al.
Pageof 9